Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORAL-21Standard

ORTHO TRI-CYCLEN 21

ETHINYL ESTRADIOL; NORGESTIMATE

Standard Dose
0.035MG,0.035MG,0.035MG; 0.18MG,0.215MG,0.25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview ORTHO TRI-CYCLEN 21 is listed in Drugs@FDA under application 021690 (NDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET; ORAL-21 - 0.035MG,0.035MG,0.035MG; 0.18MG,0.215MG,0.25MG Sponsor ORTHO MCNEIL PHARM Submission history Latest submission status date: 2015-05-01 00:00:00.

Structured Monograph

Clinical summary

Approval overview ORTHO TRI-CYCLEN 21 is listed in Drugs@FDA under application 021690 (NDA). Review priority: STANDARD Marketing status: Prescription Active ingredient ETHINYL ESTRADIOL; NORGESTIMATE Form and strength TABLET; ORAL-21 - 0.035MG,0.035MG,0.035MG; 0.18MG,0.215MG,0.25MG Sponsor ORTHO MCNEIL PHARM Submission history Latest submission status date: 2015-05-01 00:00:00. Submission type: SUPPL.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.